Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + capecitabine with or without trastuzumab for HER2-positive metastatic breast cancer after anti-HER2 therapy failure
ChiCTR2000041223Phase 4Recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pyrotinib, capecitabine and trastuzumab in breast cancer (2 arms), sponsored by Jiangxi Cancer Hospital. Primary endpoint: Disease-free survival. Started Jan 2021; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000041223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041223.